All In Biotech

Drug Trial Radar · NCT07201558

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

An Open-label, Phase I Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Surovatamig Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Dec 2, 2025

Primary completion

Jun 27, 2028

Study completion Jun 27, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.

Conditions

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus

Interventions

  • SurovatamigBiological

    Surovatamig is a bispecific T-cell engager administered subcutaneously. This is an open-label, dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Surovatamig in adult participants with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). The study consists of up to three parts: Part 1 (SAD): Single ascending dose - participants receive one dose of Surovatamig. Part 2 (sSUD): Single step-up dosing - participants receive two doses. Part 3 (dSUD): Double step-up dosing - participants receive three doses. Participants are assigned to a study part based on protocol-defined criteria. The study includes follow-up for a minimum of 179 days post-first dose, with extended monitoring up to 12 months for certain participants.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety evaluation of surovatamig: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs)Time frame: Day 1 to end of the study (up to 52 weeks)
  2. Safety evaluation of surovatamig: Frequency of dose limiting toxicities (DLTs).Time frame: Day 1 to end of the study (up to 52 weeks)
  3. Safety of surovatamig: Incidence of AEs/SAEs leading to discontinuation of surovatamigTime frame: Day 1 to end of the study (up to 52 weeks)
  4. Tolerability of surovatamig: Incidence of treatment-related vital signs abnormalitiesTime frame: Day 1 to end of the study (up to 52 weeks)
  5. Tolerability of surovatamig: Incidence of treatment-related clinical laboratory abnormalitiesTime frame: Day 1 to end of the study (up to 52 weeks)
  6. Tolerability of surovatamig: Number of participants with abnormal ECGTime frame: From baseline through Day 180.

Locations

35 sites in 10 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama · Withdrawn

  • Research Site

    Fullerton, California · Recruiting

  • Research Site

    Plantation, Florida · Not yet recruiting

  • Research Site

    St Louis, Missouri · Not yet recruiting

  • Research Site

    Allen, Texas · Recruiting

  • Research Site

    Mesquite, Texas · Recruiting

  • Research Site

    Birtinya, Australia · Recruiting

  • Research Site

    Clayton, Australia · Recruiting

  • Research Site

    Edegem, Belgium · Recruiting

  • Research Site

    Leuven, Belgium · Not yet recruiting

  • Research Site

    Liège, Belgium · Recruiting

  • Research Site

    Merksem (Antwerpen), Belgium · Recruiting

  • Research Site

    Porto Alegre, Brazil · Recruiting

  • Research Site

    Salvador, Brazil · Recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Nanjing, China · Recruiting

  • Research Site

    Bonn, Germany · Recruiting

  • Research Site

    Jena, Germany · Recruiting

  • Research Site

    Mainz, Germany · Withdrawn

  • Research Site

    München, Germany · Not yet recruiting

  • Research Site

    Münster, Germany · Not yet recruiting

  • Research Site

    Barcelona, Spain · Recruiting

  • Research Site

    Córdoba, Spain · Recruiting

  • Research Site

    Madrid, Spain · Recruiting

  • Research Site

    Kaohsiung City, Taiwan · Recruiting

  • Research Site

    Taichung, Taiwan · Recruiting

  • Research Site

    Taipei, Taiwan · Recruiting

  • Research Site

    Taoyuan, Taiwan · Recruiting

  • Research Site

    Kyiv, Ukraine · Recruiting

  • Research Site

    Ternopil, Ukraine · Recruiting

  • Research Site

    Vinnytsia, Ukraine · Recruiting

  • Research Site

    London, United Kingdom · Not yet recruiting

  • Research Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.